Ignite Creation Date:
2025-12-25 @ 1:34 AM
Ignite Modification Date:
2026-02-23 @ 6:25 AM
Study NCT ID:
NCT02163694
Status:
COMPLETED
Last Update Posted:
2025-02-19
First Post:
2014-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Sponsor:
AbbVie
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | PARP Inhibitor | View |
| None | Veliparib | View |
| None | BRCA1 | View |
| None | BRCA2 | View |
| None | HER2-negative | View |
| None | Locally recurrent | View |
| None | Breast Cancer | View |
| None | Metastatic Breast Cancer | View |
| None | ABT-888 | View |
| None | Genetic breast cancer | View |
| None | Paclitaxel | View |
| None | BRCA Mutation | View |
| None | PARP | View |
| None | Carboplatin | View |
| None | BROCADE3 | View |